Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Buy Rating from Analysts at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn has initiated coverage on Regeneron Pharmaceuticals with a "buy" rating and a price target of $890.00, suggesting a potential upside of 58.49% from the current stock price.
• Regeneron recently reported earnings of $12.89 per share, significantly beating analysts' expectations of $8.43, with quarterly revenue reaching $3.68 billion.
• The stock has a current consensus rating of Moderate Buy, with 17 analysts rating it as a buy and an average price target of $838.00.

Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) in a research note published on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $890.00 price objective on the biopharmaceutical company's stock.

Other equities research analysts have also recently issued reports about the stock. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research report on Monday, August 4th. Citigroup reissued a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $838.00.

Regeneron Pharmaceuticals Stock Up 2.6%

REGN traded up $14.44 during trading on Thursday, hitting $580.41. The company had a trading volume of 1,121,578 shares, compared to its average volume of 985,857. The company has a market capitalization of $61.52 billion, a PE ratio of 14.63, a PEG ratio of 1.93 and a beta of 0.33. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $1,211.20. The firm's 50-day moving average price is $544.21 and its 200 day moving average price is $594.90. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $11.56 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Activest Wealth Management boosted its position in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Finally, Saudi Central Bank bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $27,000. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.